Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Value-based pricing: no place to hide from the payer

As the term “value-based pricing” starts to underpin pharma discussions with the payer, pharmaphorum speaks with market access expert Omar Ali to find out what it really means. The hurdles to ensuring effective market access for new drugs seem to creep ever higher as countries around the world implement stricter cost containment…

Articles

Clinical continuity: the commercial role of phase IV studies

Are phase IV studies the poor cousin of pivotal phase III trials? Not so, postulates Riccardo Perfetti, as he explains how phase IV can redefine the market for a new drug. Effective clinical trial design has always been a critical component of ensuring new drugs receive the right commercial positioning and can reach the patients...

Articles

A beginner’s guide to digital pharma: part 16 – so long and ...

With a tear in our eye we reach the end of our beginner’s guide to digital. We hope it’s been useful and before we go, here are some closing thoughts to leave you with. So over the last nine months we have covered the “what to do” on various subjects in digital, we’ve given tips on what tools to use and mentioned…

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.